A Phase II, Open-Label, Single-Arm Trial of Pembrolizumab for Recurrent Meningioma and Solitary Fibrous Tumor.
NEURO-ONCOLOGY ADVANCES(2024)
Key words
meningioma,solitary fibrous tumor,pembrolizumab,PD-1,immunotherapy
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined